Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;5(3):240-251.
doi: 10.1038/s41551-020-00638-0. Epub 2020 Nov 30.

A portable single-sided magnetic-resonance sensor for the grading of liver steatosis and fibrosis

Affiliations

A portable single-sided magnetic-resonance sensor for the grading of liver steatosis and fibrosis

Ashvin Bashyam et al. Nat Biomed Eng. 2021 Mar.

Abstract

Low-cost non-invasive diagnostic tools for staging the progression of non-alcoholic chronic liver failure from fatty liver disease to steatohepatitis are unavailable. Here, we describe the development and performance of a portable single-sided magnetic-resonance sensor for grading liver steatosis and fibrosis using diffusion-weighted multicomponent T2 relaxometry. In a diet-induced mouse model of non-alcoholic fatty liver disease, the sensor achieved overall accuracies of 92% (Cohen's kappa, κ = 0.89) and 86% (κ = 0.78) in the ex vivo grading of steatosis and fibrosis, respectively. Localization of the measurements in living mice through frequency-dependent spatial encoding led to an overall accuracy of 87% (κ = 0.81) for the grading of steatosis. In human liver samples, the sensor graded steatosis with an overall accuracy of 93% (κ = 0.88). The use of T2 relaxometry as a sensitive measure in fully automated low-cost magnetic-resonance devices at the point of care would alleviate the accessibility and cost limits of magnetic-resonance imaging for diagnosing liver disease and assessing liver health before liver transplantation.

PubMed Disclaimer

Comment in

  • Device downsizing via signal enhancement.
    [No authors listed] [No authors listed] Nat Biomed Eng. 2021 Mar;5(3):195-196. doi: 10.1038/s41551-021-00708-x. Nat Biomed Eng. 2021. PMID: 33727712 No abstract available.

References

    1. Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11–20 (2018). - PubMed - DOI
    1. Shetty, A. & Syn, W.-K. Health and economic burden of nonalcoholic fatty liver disease in the United States and its impact on veterans. Fed. Pract. 36, 14–19 (2019). - PubMed - PMC
    1. Spengler, E. K. & Loomba, R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clin. Proc. 90, 1233–1246 (2015). - PubMed - DOI
    1. Brunt, E. M. Pathology of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 7, 195–203 (2010). - PubMed - DOI
    1. Vernon, G., Baranova, A. & Younossi, Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34, 274–285 (2011). - PubMed - DOI

Publication types

LinkOut - more resources